Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyMass General Brigham Health Plan specialty PA code…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentMass General Brigham Health PlanPolicy N/A

    Medical Specialty Medications — MassHealth Prior Authorization Code List

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists medical specialty medications and associated billing codes and attributes for MassHealth prior authorization effective 05/01/2026; it governs prior authorization handling for these specialty drugs under the Mass General Brigham Health Plan for the MassHealth program.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyMedical Specialty Medications — MassHealth Prior Authorization Code List
    Policy CodePolicy N/A
    Change TypeInformational update (code/attribute roster)
    Effective DateMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionUse the listed HCPCS/J/Q codes and associated flags (Dual Benefit, HCT, DW Program, PD-1 weight‑based dosing, IVIG dose optimization) when processing prior authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+medications listed in this excerpt
    manydistinct HCPCS/J- and Q-codes
    presentIVIG Dose Optimization flagged
    presentHCT flags indicated
    someDW Program flags

    Coverage criteria and administrative flags

    Medication code inventory

    Code list with attributes — the document provides a roster of specialty medication billing codes and per-code administrative flags; no itemized clinical medical-necessity rules are included in this section.

    ALL of the following

    • Provides HCPCS/J/Q code entries with Brand Name and Generic Name where available (e.g., Q5145 Abrilada / adalimumab-afzb; J3262 Actemra IV / tocilizumab).
    • Each code entry includes administrative attributes: Dual Benefit, HCT (hematopoietic cell transplant), DW Program (Drug Wastage Program), PD-1 Weight Based Dosing, and IVIG Dose Optimization with Y/N or blank values.
    • This section is an inventory; it does not define clinical coverage criteria or step-therapy rules within these chunks.

    ALL of the following

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyMedical Specialty Medications — MassHealth Prior Authorization Code List
    Policy CodePolicy N/A
    Change TypeInformational update (code/attribute roster)
    Effective DateMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionUse the listed HCPCS/J/Q codes and associated flags (Dual Benefit, HCT, DW Program, PD-1 weight‑based dosing, IVIG dose optimization) when processing prior authorization requests.
    SourceLink
    On This Page
    Coverage criteria and administrative flagsHCPCS / J- / Q-code listings and attributesWhat providers must know and do (billing & prior auth impacts)Flags and attribute definitions
    Examples of listed codes and attributes: Q5145 (Abrilada) — Dual Benefit = Y; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N.
  1. J3262 (Actemra IV) — Dual Benefit = .; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N.
  2. ALL of the following

    • IVIG and subcutaneous immune globulin products are present in the inventory and are explicitly marked where IVIG Dose Optimization applies (e.g., J1554 IVIG — IVIG Dose Optimization = Y; J1551/Cutaquig and J1555/Cuvitru — IVIG Dose Optimization = Y).

    Coverage stance for listed medications

    Top-level observation on coverage stance and document purpose:

    ALL of the following

    • The listed entries present code-level information and administrative flags intended to inform prior-authorization processing (Dual Benefit, HCT, DW Program, PD-1 weight-based dosing, IVIG Dose Optimization).
    • The excerpt does not include itemized medical necessity rules, clinical criteria, or explicit coverage determinations for individual diagnoses or indications; it functions as an administrative inventory to guide routing and handling during prior authorization review.

    ALL of the following

    • Some codes are marked HCT = Y, indicating relevance for hematopoietic cell transplant workflows (examples in this excerpt include J9321 and Q5151 listed with HCT = Y).
    • Dual Benefit is indicated for a subset of products (flagged as Y) and will affect billing/benefit handling where applicable.

    Administrative coverage flags and meaning

    Definitions and operational meaning of per-entry administrative flags used in prior-authorization handling:

    Dual Benefit: Y indicates the product is designated as Dual Benefit for billing/benefit purposes; blank or period indicates not flagged.
    HCT (*): Y indicates the medication is marked as related to hematopoietic cell transplantation and may route to transplant-specific review; N indicates not flagged.
    DW Program (Drug Wastage Program): Y indicates the product is included in the drug-wastage program; N indicates not included.
    PD-1 Wt Based Dosing: Y indicates the PD‑1 class drug requires weight‑based dosing handling; N indicates standard dosing handling (examples: some nivolumab/opdivo entries are flagged for PD‑1 handling).

    See PD‑1 weight‑based dosing flags for nivolumab/opdivo class entries.

    IVIG Dose Optimization: Y indicates IVIG dose‑optimization rules apply to the product (applies to certain IVIG/subcutaneous immune globulin entries); N indicates not applicable.

    Partial medication entries

    Representative partial entries from the roster (attributes shown as recorded in the source):

    ALL of the following

    • J2327 — IVIG Dose Optimization = N (entry present in partial list).
    • J7331 — Brand: Sodium hyaluronate; HCT = N; Dual Benefit = . (no Dual Benefit flag).
    • J1299 — Brand: Soliris; Generic: eculizumab; HCT = Y (marked for HCT relevance).

    Coverage stance (partial)

    Summary observations for the specialty medication coding excerpt (partial):

    ALL of the following

    • The excerpt enumerates additional HCPCS/J/Q codes with brand/generic names and repeated administrative flags (Dual Benefit, HCT, DW Program, PD‑1 Wt Based Dosing, IVIG Dose Optimization) for routing and prior‑authorization handling.
    • This portion does not provide explicit medical necessity criteria or step‑therapy rules for these specialty medications; it should be used as an administrative inventory to support authorization workflows.

    ALL of the following

    • Examples in this partial excerpt: Q5100 (Yesintek SQ — ustekinumab-kfce) marked Dual Benefit = Y; J9278 (Yimmugo — intravenous immune globulin) marked IVIG Dose Optimization = Y; J1748 (infliximab-dyyb) marked Dual Benefit = Y.

    HCPCS / J- / Q-code listings and attributes

    sample specialty medication codesHCPCS | mixedCovered
    Q5145Abrilada (adalimumab-afzb)
    J3262Actemra IV (tocilizumab)
    J0791Adakveo (crizanlizumab-tmca)
    J9042Adcetris (brentuximab vedotin)
    sample J/Q HCPCS codes from excerptHCPCSCovered
    J3380listed with various flag values (Benefit = Y; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N)
    Q5149Enzeevu (aflibercept-abzv) with flags shown
    J9321Epkinly (epcoritamab-bysp) with HCT = Y
    Q5151Epysqli (eculizumab-aagh) with HCT = Y
    sample medication code mappings (partial)CPTCovered
    J3590Loargys / pegzilarginase-nbln or other products reported to J3590 (multiple brand mappings in list)
    J0221Lumizyme / alglucosidase alfa
    Q5107Mvasi / bevacizumab-awwb
    J9299Opdivo / nivolumab (see PD-1 weight-based dosing flag)
    Examples of J-codes and associated brands/generics in this extractHCPCS
    J1299eculizumab (Soliris)
    J1747spesolimab-sbzo (Spevigo) — IV and SQ entries
    J3357ustekinumab (Stelara) SQ
    listed_specialty_medicationsHCPCS
    Q5100ustekinumab-kfce / Yesintek SQ (brand/generic indicated)
    J9278intravenous immune globulin / Yimmugo
    Q5141adalimumab-aaty / Yuflyma
    J3590adalimumab-aqvh / Yusimry
    J9400ziv-aflibercept / Zaltrap
    J9223lurbinectedin / Zepzelca
    J9276zanidatamab / Ziihera
    J3304triamcinolone acetonide / Zilretta
    Q5118bevacizumab-bvzr / Zirabev
    J9202goserelin acetate implant / Zoladex
    1–10 of 14
    1/2
    inv-11: IVIG Dose Optimization flag — Y/N per code entry
    IVIG Dose Optimization — presenceFlag shown per code entry as Y or N (e.g., J1552 IVIG Dose Optimization = Y; many entries show N)
    MeaningIndicates whether IVIG dose optimization applies to the product
    Representation in listShown as 'IVIG Dose Optimization *+ = Y' or '... = N' next to each code
    inv-12: PD-1 weight-based dosing flag — indication for some nivolumab entries
    PD-1 Weight‑Based Dosing — presenceFlag shown per code entry as Y or N (e.g., J9299 PD-1 Wt Based Dosing = Y)
    Applies toPD‑1 class agents (example: nivolumab / J9299 marked Y)
    Representation in listShown as 'PD-1 Wt Based Dosing *+ = Y' or '... = N' next to each code

    What providers must know and do (billing & prior auth impacts)

    Prior Authorization

    Specialty medication code and attribute list — codes and flags

    Q5145 (Abrilada) — adalimumab-afzb; Dual Benefit = Y; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N. J3262 (Actemra IV) — tocilizumab; Dual Benefit = .; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N. J0791 (Adakveo) — crizanlizumab-tmca; Dual Benefit = .; HCT = N; DW Program = Y; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N. J9042 (Adcetris) — brentuximab vedotin; Dual Benefit = .; HCT = N; DW Program = Y; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N. J7171 (Adzynma) — ADAMTS13, recombinant-krhn; Dual Benefit = Y; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N. Q5150 (Ahzantive) — aflibercept-mrbb; Dual Benefit = .; HCT = N; DW Program = N; PD-1 Wt Based Dosing = N; IVIG Dose Optimization = N.

    Documentation Required

    Specialty medication listing and flags — document these attributes on PA

    Entries include code, brand/generic name, and administrative flags; providers must document code-specific attributes on prior authorization requests (e.g., Dual Benefit, HCT, DW Program, PD-1 weight‑based dosing, IVIG Dose Optimization) because these flags determine routing and handling during PA processing.

    • Example entries: J3380 (flags: Dual Benefit = Y; HCT = N; DW Program = N; PD‑1 Wt Based Dosing = N; IVIG Dose Optimization = N)
    • Q5149 (Enzeevu) — HCT = N; DW Program = N; IVIG Dose Optimization = N
    • J9321 (Epkinly) — HCT = Y; DW Program = N; IVIG Dose Optimization = N
    Prior Authorization

    Medication code list and flags (partial) — PA-relevant flags shown

    Q5107 (Mvasi) — bevacizumab-awwb; J0221 (Lumizyme) — alglucosidase alfa; J1568 (Octagam) — intravenous immune globulin (IVIG Dose Optimization = Y); J2350 — PD‑1 Wt Based Dosing = N. These partial entries include program flags relevant to prior authorization handling.

    • J1568 (Octagam): IVIG Dose Optimization = Y; Dual Benefit = Y; HCT = N
    • J2350: PD‑1 Wt Based Dosing = N; IVIG Dose Optimization = N
    • Q5107 and J0221 shown as part of the partial code list
    Prior Authorization

    Specialty medication code list (partial) — HCPCS/J/Q codes with flags

    Selected HCPCS entries with flags: J2327 (IVIG Dose Optimization = N); J7331 (Sodium hyaluronate) — Dual Benefit = .; HCT = N; Q5114 (Ogivri) — IVIG Dose Optimization = N; J3590 (Somavert) — Dual Benefit = Y. Providers should reference these flags when submitting PA requests.

    • J1299 (Soliris): HCT = Y; IVIG Dose Optimization = N
    • J3590 (Somavert): Dual Benefit = Y; IVIG Dose Optimization = N
    • J1747 (Spevigo IV/SQ): Dual Benefit = Y; IVIG Dose Optimization = N
    Documentation Required

    Specialty medication code attributes (partial) — flags to include on PA

    Attributes shown for select codes include brand/generic and markers such as Dual Benefit, HCT, DW Program, PD‑1 Wt Based Dosing, and IVIG Dose Optimization. Examples: Q5100 (Yesintek SQ) — Dual Benefit = Y; J9278 (Yimmugo) — IVIG Dose Optimization = Y; Q5141 (Yuflyma) — Dual Benefit = Y.

    • Q5100: Brand Yesintek SQ; Generic ustekinumab-kfce; Dual Benefit = Y; IVIG Dose Optimization = N
    • J9278: Brand Yimmugo; IVIG Dose Optimization = Y
    • Q5141 and J3590 (Yusimry): Dual Benefit = Y
    Documentation Required

    Additional specialty medication entries — include flag details on PA

    Additional listed entries require flag-aware submission: J9223 (Zepzelca) — DW Program = N; J9276 (Ziihera) — DW Program = N; J1748 (Zymfentra / infliximab-dyyb) — Dual Benefit = Y. Include these code flags in PA paperwork to ensure correct program routing.

    • J9223: DW Program = N; IVIG Dose Optimization = N
    • J9276: Dual Benefit = .; DW Program = N
    • J1748: Dual Benefit = Y; HCT = N

    Flags and attribute definitions

    inv-19: Dual Benefit indicator
    Dual Benefit — indicatorMarks whether product is designated Dual Benefit; values shown as 'Y' or blank/period (examples: Q5145 = Y; Q5100 = Y; J1748 = Y)
    MeaningIndicates dual benefit billing/status for the listed product
    Representation in listShown as 'Dual Benefit = Y' or 'Dual Benefit = .' next to each code
    inv-20: HCT flag definition
    HCT flag — presenceFlag shown per code as HCT * = Y or N (used to indicate hematopoietic cell transplant relevance)
    ExamplesJ1931 HCT * = Y; J1426 HCT * = Y; J1299 HCT * = Y
    Representation in listShown as 'HCT * = Y' or 'HCT * = N' next to each code
    inv-21: IVIG Dose Optimization definition
    IVIG Dose Optimization — definitionFlag indicating whether IVIG dose optimization applies to the product (Y/N)
    ExamplesJ1552 IVIG Dose Optimization = Y; J1568 IVIG Dose Optimization = Y; J2327 IVIG Dose Optimization = N
    RepresentationShown as 'IVIG Dose Optimization *+ = Y' or '... = N' next to each code
    inv-22: HCT flag (as shown next to codes)
    HCT flag (code display)Displayed as 'HCT * = Y' or 'HCT * = N' next to codes to indicate transplant relevance
    Used forRouting/prior authorization handling when medication is transplant‑related
    ExamplesJ0221 HCT * = Y; J1299 HCT * = Y
    inv-23: Drug Wastage (DW) Program flag
    Drug Wastage (DW) Program flag — presenceDisplayed per code as 'DW Program* + = Y' or '... = N' to indicate DW Program applicability
    ExamplesJ0791 DW Program* + = Y; J9042 DW Program* + = Y; Q5141 DW Program* + = N
    RepresentationShown as 'DW Program* + = Y' or '... = N' next to each code
    inv-24: Indicator for intravenous immune globulin dose optimization
    IVIG Dose Optimization — indicatorMarks intravenous immune globulin dose optimization applicability per product (Y/N)
    ExamplesJ1552 = Y; J1568 = Y; J9278 = Y
    Shown as'IVIG Dose Optimization *+ = Y' or '... = N' adjacent to code entries
    inv-25: HCT * = Y/N indicates whether marked as related to hematopoietic cell transplant
    HCT * = Y/N — marker meaningAsterisked HCT field indicates whether medication is related to hematopoietic cell transplant (Y or N)
    ExamplesJ0221 HCT * = Y; J1426 HCT * = Y; J1299 HCT * = Y
    RepresentationDisplayed 'HCT * = Y' or 'HCT * = N' next to each code
    inv-26: PD-1 Wt Based Dosing *+ = Y/N indicates whether PD-1 class drugs require weight-based dosing handling
    PD‑1 Wt Based Dosing *+ = Y/N — marker meaningIndicates whether PD‑1 class drugs require weight‑based dosing handling (example: J9299 Opdivo marked Y)
    ExamplesJ9299 PD-1 Wt Based Dosing *+ = Y; most other PD‑1 entries shown as N
    RepresentationShown as 'PD-1 Wt Based Dosing *+ = Y' or '... = N' next to codes
    inv-27: IVIG Dose Optimization flag — indicates whether IVIG dose optimization applies (Y/N)
    IVIG Dose Optimization — flag (repeat)Indicates per‑code whether IVIG dose optimization applies; shown as Y or N (e.g., J1552 = Y; J2327 = N)
    PurposeUsed to identify products subject to IVIG dose optimization during prior authorization
    Representation'IVIG Dose Optimization *+ = Y' or '... = N' displayed beside the HCPCS/J/Q code
    inv-28: HCT * — indicates hematopoietic cell transplant relevance (Y/N)
    HCT * — transplant relevanceFlag denotes hematopoietic cell transplant relevance (Y or N) and is shown next to codes
    ExamplesJ1426 HCT * = Y; J1299 HCT * = Y; several others HCT * = N
    RepresentationShown as 'HCT * = Y' or 'HCT * = N' in the code attribute column
    inv-29: Dual Benefit — marker indicating dual benefit status (Y or blank/period)
    Dual Benefit — markerIndicates dual benefit status; values are 'Y' or '.' (blank/period) — used on many entries (examples: Q5145 = Y; J3590 entries vary)
    MeaningSignals dual benefit billing/status for the medication
    RepresentationDisplayed as 'Dual Benefit = Y' or 'Dual Benefit = .' adjacent to each code
    inv-30: code attributes — fields per code include Brand Name, Generic Name, Dual Benefit, HCT, DW Program, PD-1 Wt Based Dosing, IVIG Dose Optimization
    Code attributes — fields shown per codeBrand Name, Generic Name, Dual Benefit, HCT (HCT *), DW Program (DW Program* +), PD-1 Wt Based Dosing (PD-1 Wt Based Dosing *+), IVIG Dose Optimization (IVIG Dose Optimization *+)
    PurposeAttributes used to route and apply prior authorization handling and program flags
    RepresentationEach attribute displayed as 'field = value' next to the HCPCS/J/Q code in the list